Review Group Reports On Breast, Prostate Cancer Pose Challenges for NCI

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 11
Volume 7
Issue 11

BETHESDA, Md--The reports of the progress review groups on prostate and breast cancers present the National Cancer Institute (NCI) with both opportunities and challenges, director Richard D. Klausner, MD, told the National Cancer Advisory Board.

 BETHESDA, Md--The reports of the progress review groups on prostate and breast cancers present the National Cancer Institute (NCI) with both opportunities and challenges, director Richard D. Klausner, MD, told the National Cancer Advisory Board.

"Here are the oncology communities coming together and saying: This is what we need," Dr. Klausner said. The challenge for the Institute, he said, is how to satisfy each panel’s recommendations and create a knowledge base for each cancer "in our environment of investigator initiated research filtered through peer-review."

He said the two reports are being analyzed by NCI staff to develop ways to respond, adding that he expects to see specific new programs and requests for research applications emerging as a result of the recommendations. "For the Institute, the affected fields, and, I think, all of the other agencies involved in funding research in these areas, these two reports are going to be very influential," he commented.

Dr. Klausner noted the overlap in some of the major recommendations made by the two panels, such as a greater emphasis on understanding the basic biology of breast and prostate cancer. This has raised a question, still unresolved within NCI, of whether the institute should organize additional peer review groups to address other cancers, including lung, colorectal, and ovarian. "If we do," he said, "what do we learn from the tremendous overlap in recommendations?"

Recent Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Related Content